Clinical Trial of Tolcapone for Cognition in Schizophrenia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. ...

Key facts

Study ID
NCT00044083
Run by
National Institute of Mental Health (NIMH)
People needed
210
Starts
2002-08-01
Expected to finish
2015-12-01
Last updated by the study team
2018-09-27

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.